J 2023

Antimicrobial effect of endolysins LYSDERM‐S and LYSDERM‐T1 and endolysin‐ubiquitin combination on methicillin‐resistant Staphylococcus aureus

VACEK, Lukáš, Michaela KOUŘILOVÁ, Šárka KOBZOVÁ and Lubomír JANDA

Basic information

Original name

Antimicrobial effect of endolysins LYSDERM‐S and LYSDERM‐T1 and endolysin‐ubiquitin combination on methicillin‐resistant Staphylococcus aureus

Authors

VACEK, Lukáš (203 Czech Republic, belonging to the institution), Michaela KOUŘILOVÁ (203 Czech Republic), Šárka KOBZOVÁ (203 Czech Republic) and Lubomír JANDA (203 Czech Republic, guarantor)

Edition

BIOLOGIA, NEW YORK, SPRINGER, 2023, 0006-3088

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10606 Microbiology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 1.500 in 2022

RIV identification code

RIV/00216224:14110/23:00134618

Organization unit

Faculty of Medicine

UT WoS

000894986000002

Keywords in English

Endolysin;Ubiquitin;LYSDERM-S;LYSDERM-T1;Staphylococcus aureus;MRSA

Tags

Tags

International impact, Reviewed
Změněno: 24/2/2023 08:14, Mgr. Tereza Miškechová

Abstract

V originále

Bacterial resistance is a major issue in the modern world, and Staphylococcus aureus is one of these well-known multi-resistant species. Staphylococcal infections are one of the leading causes of infection in humans and are becoming more challenging to treat by conventional methods. Endolysins, a novel class of antibacterial agents, are bacteriophage-encoded lytic enzymes capable of degrading peptidoglycan and thus able to kill bacteria. This study aimed to study endolysin LYSDERM-S (a variant of endolysin LysF1 optimized for heterologous expression in E. coli) and newly prepared thermally stabilized endolysin LYSDERM-T1 (with a mutation in the CHAP domain) both with (LYSDERM-US, LYSDERM-UT1) and without fused ubiquitin and determine its role in protein expression and antibacterial activity. The results showed that fused endolysin-ubiquitin proteins did not exceed the antimicrobial effect of endolysins alone, but cleaved endolysin-ubiquitin proteins possessed longer lasting antimicrobial effect than endolysin alone. The biobetter endolysin LYSDERM-T1 with higher thermal stability showed a prolonged antimicrobial effect. Further, we showed that ubiquitin alone possesses antimicrobial properties. Minimal inhibitory and bactericidal concentrations (MIC and MBC) were assessed and confirmed that ubiquitin is able to increase the antimicrobial potential of endolysins. Biobetter endolysins or endolysin-ubiquitin combinations could serve as an alternative to well-established antimicrobial therapy for methicillin-resistant S. aureus infections.

Links

NU22-05-00475, research and development project
Name: Léčba infekcí způsobených multirezistentními kmeny bakterií pomocí nových antibakteriálních přípravků založených na katelicidinových antimikrobiálních peptidech
Investor: Ministry of Health of the CR, Subprogram 1 - standard